Table 1.
Characteristics of the included RCTs.
| Study ID | Sample size (T/C) | Age (year) | Sex (M/F) | Intervention | Outcome measure | Acupoints | |
|---|---|---|---|---|---|---|---|
| Treatment group | Control group | ||||||
| Hou, 2011 | 40 (20/20) | T: 59.20 ± 9.80 | T: 11/9 | Acupuncture | Cobaltine adenosine | NCI-CTC | LI11, PC6, LI4, ST36, SP6, and GB34 |
| C: 62.95 ± 10.85 | C: 8/12 | ||||||
| Mai, 2008 | 60 (30/30) | T: 50.35 | T: 20/10 | Acupuncture | VB1 + VB12 | PNQ | GB20, TE5, ST36, BL40, GB34, ST40, SP6, LR3, and SP10 |
| C: 51.12 | C: 21/9 | ||||||
| Yan, 2012 | 75 (36/39) | T: 52.5 ± 5.63 | T: 20/16 | Acupuncture | VB1 + VB12 | PNQ | LI4, LI11, EX-UE9, LR3, ST36, SP10, and EX-LE10 |
| C: 51.3 ± 6.17 | C: 28/11 | ||||||
| Xu, 2010 | 64 (32/32) | T: 38∼77 | T: 17/15 | Acupuncture | VB1 + VB12 | PNQ | LI4, LR3, ST36, CV6, LI11, SP3, EX-UE9, and EX-LE10 |
| C: 41∼83 | C: 16/16 | ||||||
| Liu, 2009 | 60 (30/30) | T: 64.8 | T: 16/14 | Acupuncture | Cobaltine adenosine | Levi | LI11, LI4, ST36, SP6, GB34, KI16, CV6, and CV4 |
| C: 62.6 | C: 17/13 | ||||||
| Cui, 2011 | 62 (32/30) | T: 59.6 | T: 19/13 | Acupuncture | Cobaltine adenosine | Levi | LI11, TE5, SI3, LI4, SJ3, SP9, ST36, GB34, SP6, GB39, and KI6 |
| C: 58.8 | C: 20/10 | ||||||
| Chen, 2018 | 80 (40/40) | T: 49.02 ± 8.63 | T: 24/16 | Acupuncture | Mecobalamin | RECIST | ST36, CV6, SP3, LI4, LI11, LR3, EX-UE9, and EX-LE10 |
| C: 48.75 ± 8.67 | C: 25/15 | ||||||
| Wang, 2011 | 60 (30/30) | T: 63.7 ± 9.8 | T: 16/14 | Acupuncture | Cobaltine adenosine | PNQ | LI4, LI10, LI1, ST32, ST36, ST40, GB30, GB31, GB34, EX-UE9, and EX-LE10 |
| C: 61.6 ± 8.9 | C: 17/13 | ||||||
| Tian, 2016 | 60 (30/30) | T: 60.9 ± 10.7 | T: 18/12 | Acupuncture | Cobaltine adenosine | PNQ, NCV, and QOL | LI10, LI11, LI4, TE5, EX-UE9, GB34, ST40, SP6, ST36, GB40, LR3, EX-LE10, CV4, CV6, and GV20 |
| C: 62.7 ± 10.4 | C: 17/13 | ||||||
| Han, 2017 | 98 (49/49) | — | T: 27/22 | Acupuncture | Cobaltine adenosine | VAS, NCV | LR3, ST43, GB4, SP6, ST36, SP10, ST25, GV14, GV12, GV11, GV9, and BL13 (BL17, BL58) |
| — | C: 29/20 | FACT/GOG-NTX | |||||
| Sun, 2012 | 66 (34/32) | T: 64 | T:24/10 | Electroacupuncture | Reduced glutathione | Levi, NCV | ST36, SP10, CV4, LI11, LI4, SJ10, TE4, LI5, SI4, EX-UE9, SI3, ST35, ST34, SP9, SP6, ST41, KI3, BL60, BL62, KI6, LR3, and EX-LE10 |
| C: 61 | C: 22/10 | ||||||
| Tian, 2011 | 76 (38/38) | T: 54.9 | T: 24/14 | Acupuncture | Neurotropin | Levi, KPS | LI4, TE5, LI5, LI10, LI11, LR3, ST36, GB34, CV6, ST40 |
| C:52.7 | C: 20/18 | ||||||
| Zhang, 2018 | 30 (15/15) | T: 52.46 ± 10.06 | T: 10/5 | Electroacupuncture | VB1 + VB12 | Levi, KPS | LI11, LI10, LI4, ST36, ST40, ST44 |
| C: 56.80 ± 8.06 | C: 8/7 | ||||||
| Greenlee, 2016 | 63 (31/32) | T:51.8 | — | Electroacupuncture | Sham acupuncture | BPI-SF, FACT-NTX | GB34, ST36, LI4, LI10, L3, L5, C5, and C7 |
| C:48.3 | — | ||||||
| Molassistis, 2019 | 87 (44/43) | — | T: 9/35 | Acupuncture | VB6 + VB12 | BPI, FACT-NTX | If upper limbs were involved, we used LI4, LI11, PC7, TE5, and/or Ex-UE9; if lower limbs were affected (most common), we used SP6, ST36, LV3, ST41, and/or Ex-LE10 |
| — | C: 15/28 | Neuropathy score | |||||
| Rostock, 2013 | 29 (14/15) | T:49.9 ± 9.6 | T: 4/10 | Electroacupuncture | VB6 + VB1 | NCI-CTC, NRS | LV3, SP9, GB41, GB34, LI4 , LI11 , SI3 , and HT3 |
| C:56.3 ± 11.1 | C: 5/10 | Neuropathy score, NCV, and QLQ-C30 | |||||
| Wu, 2018 | 40 (20/20) | T:57.10 | T: 13/7 | Acupuncture | Mecobalamin | Levi | LI11, PC6, LI4, ST36, SP6, and SP10 |
| C:57.63 | C: 14/5 | ||||||
| Lu, 2019 | 40 (20/20) | T:54.0 | T: 0/20 | Acupuncture | Usual care | PNQ, FACT-NTX, BPI-SF, and EORTC QLQ-C30 | Yin Tang, LI11, TW5, Ex-UE9, SP3, ST36, SP6, K3, and LR3 |
| C:53.5 | C: 0/20 | ||||||
| Alessandro, 2019 | 21 (12/9) | — | — | Acupuncture | Usual care | NCI-CTC, EORTC QLQ-C30, FIM, and VAS | Yuan points of the hands and feet (LR3, SP3, KI3, HT7, PC7, and LU9) plus SP9 and wrist-ankle technique (areas 1–3) |
| — | — | ||||||
Abbreviations: T: Treatment Group; C: Control Group; NCI-CTC: National Cancer Institute Common Toxicity Criteria; PNQ: Patient Neurotoxicity Questionnaire; RECIST: Response Evaluation Criteria in Solid Tumors; NCV: Nerve Conduction Velocity; QOL: Quality of Life; VAS: Visual Analogue Scale; KPS: Karnofsky; MDASI: MD Anderson Symptom Inventory: BPI-SF, Brief Pain Inventory-short form; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30; FACT-NTX, Functional Assessment of Cancer Therapy-Neurotoxicity subscale; FIM: Functional Independence Measure.